Untitled Document
[an error occurred while processing this directive]
01 - 15 January 2012  
Untitled Document

Pharma Ally
Pharma Life


Express Biotech

Editorial Advisory Board
Open Forum
Media Kit
Contact Us
Network Sites
Express Computer
Express Channel Business
Express Hospitality
Express TravelWorld
Express Healthcare
Group Sites
Indian Express
Financial Express

[an error occurred while processing this directive]

[an error occurred while processing this directive]

[an error occurred while processing this directive]
Home - Pharma Ally - Article

Importance of visual observations in dissolution testing

Kavita Singh, Aditya Marfatia and Amrita Bajaj give an outlook about various aspects of dissolution testing

Dissolution testing is a critical methodology which is widely utilised in the development of a new pharmaceutical product. The test, in its simplest form, consists of placing the formulation in a dissolution apparatus containing suitable dissolution medium, allowing it to dissolve over a specified period of time and then assaying the resultant solution using appropriate analytical method to determine the amount of drug. Dissolution tests are relevant for an array of investigations like drug degradation profiles, stability and shelf life studies, physical and mechanical testing of dosage forms, incoming quality control (QC) testing on raw materials etc.

The dissolution test is a vital tool for formulation optimisation, method development, formulation changes, manufacturing changes, process modifications to comply with regulatory requirement, US Pharmacopoeia (USP) compliance, in-vitro in-vivo correlation (IVIVC) and Scale Up and Post Approval Changes (SUPAC). As the drug moves into production, dissolution test becomes a QC test, which helps to understand outcomes of process and manufacturing changes on dissolution profile. When a new supplier for a certain excipient needs to be selected or when a new lot of excipient is used in the formulation the dissolution profile is investigated. Dissolution test helps in determining whether a drug lot passes or fails as per pharmacopeial standards. Finally as the drug moves into generic arena, dissolution test is one test, which helps to prove bio-equivalence of the generic drug with the patent protected innovative drug in the market. During all these stages, formulation scientists are always looking for ways to find a correlation between the in-vitro dissolution test and in-vivo drug concentration profile (IVIVC). Dissolution studies also provide means to control the quality of many of the parameters of a solid oral dosage form for both batch release and stability testing. This test can provide a much greater amount of value, in addition to providing a metric for quality control and stability testing. The test can be used to investigate a number of critical processing and formulation properties, in order to develop and produce a more robust and better quality drug product. A number of metrics like disintegration time, time for 50 per cent drug release, Q10, Q90 etc. are available to improve the information obtained from dissolution test. One commonly overlooked metric that can provide a host of information about the dosage unit under study is a visual observation of façade of dosage form during dissolution process. The stature of the dosage form is a simple physical observation, which may be followed by the notebook documentation of the photograph. A digital image captured to support the observation, or even live video obtained with a dedicated visual imaging system will enhance the value of the results.

USP considerations for visual observations of dissolution testing

USP 34 chapter <1092> on Dissolution Procedure, Development and Validation, states the significance of visual observation for disintegration studies of both immediate release and extended release formulations. For immediate-release dosage forms, the duration of the procedure is typically 30 to 60 minutes. In most cases, a single time point specification is adequate for pharmacopoeial purposes. Industrial and regulatory concepts of product comparability and performance may require additional time points, which may also be required for product registration or FDA approval. A sufficient number of time points should be selected to adequately characterise the ascending and plateau phases of the dissolution curve. According to the Biopharmaceutical Classification System referred in several FDA guidelines, highly soluble and highly permeable drugs formulated with rapidly dissolving products need not be subjected to a profile comparison if they can be shown to release 85 per cent or more of the active drug substance within 15 minutes. In such cases visual assessment plays a key role in understanding the pattern of dosage form dissolution pattern.

Dissolution profiles of immediate-release products typically show a gradual increase reaching 85 per cent to 100 per cent at about 30 to 45 minutes. Thus, observation for the dissolution time points in the range of 15, 20, 30, 45, and 60 minutes are usual for most immediate-release products. For rapidly dissolving products, including suspensions, useful information may be obtained from earlier points, e.g., five to 10 minutes. For slower-dissolving products, time points later than 60 minutes are useful.

For an extended-release dosage form, at least three test time points are chosen to characterise the in vitro drug release profile for pharmacopeial purposes. An early time point, usually one to two hours, is chosen to show that there is little probability of dose dumping. A visual inspection can give a fair idea of uncontrolled release pattern in such cases. During the intermediate and a final time points the in-vitro release profiles show the essentially complete release of the drug, which could be visually ensured by the complete disintegration of the dosage form. When using an automated system operated by the software, we need to be confident that the instrument is functioning the way it is programmed especially during the overnight studies where constant monitoring is practically not possible.

Conditions entailing visual observation of dissolution testing

One of the most useful tools for identifying sources of error is close observation of the test. A trained analyst can pinpoint many problems because he understands the consequences and effect of certain observations. Accurate, meaningful dissolution occurs when the product dissolves without disturbance from barriers to dissolution, or disturbance of vessel hydrodynamics from any source. The particle disintegration pattern must show freely dispersed particles. Some of the conditions where visual observations could be valuable are listed below:

1. Physical state of dosage form in dissolution medium: Dissolution of drug in the medium depends on some basic physical states like dancing or spinning of the dosage unit or the dosage unit being hit by the paddle, such miniscule behaviour is critical when assessing IVIVC. Large floating particles or chunks of the dosage unit present should be noted and correlated with the analytical data obtained. Observations must be made during complex disintegration of the coating of modified or enteric-coated products. For example, the partial opening and splitting apart or incomplete opening of the shell accompanied by the release of air bubbles and excipients, needs to be monitored. It's important to observe the adhesion of particles to the paddle or the inside of the basket upon removal of the stirring device at the end of the run. The percentage reduction in size of the dosage unit within a certain time frame is evidently recorded through visual monitoring and imaging.

2. Dissolution testing of MUPS: There is a growing interest in the area of multi unit particulate (MUPS) delayed release systems but carrying out dissolution studies for MUPS to obtain clinically relevant data is a tedious job. The observation of coarse and fine particles emitting during the dissolution of MUPS could give a unique insight into production of the dosage form. Dissolution process from MUPS follows diffusion on contact with aqueous fluids causing water diffusion into the interior of the particle. Drug dissolution occurs and the drug solutions diffuse across the release coat to the exterior. Some coatings can be designed to erode gradually with time, thereby releasing the drug contained within the particle. Further it follows osmosis, which allows water to enter and osmotic pressure can be built up within the interior of the particle. The drug is forced out of the particle into the exterior through the coating. Therefore it is very important to monitor these episodes visually.

Figure 1: Screenshot of iDisso showing magnified jar 1 along with the view of remaining five jars

3. Characteristic pattern shown by the dosage form during dissolutioprocess: Along with good documentation, familiarity with the dissolution behaviour of a product is essential in quickly identifying changes in stability or changes associated with a modification of the formulation. One may notice a change in the size of the dissolving particles, excipients floating upward, or a slower erosion pattern. Changes in the formulation or an increase in strength may produce previously unobserved basket screen clogging. If contents of the basket immediately fall out and settle to the bottom of the vessel, a spindle assembly surge might be indicated. All such issues may be identified and rectified using data capturing and imaging system.

4. Visual observations of light sensitive drugs: Recordings of product dissolution and disintegration behaviour are very useful because dissolution and disintegration patterns can be indicative of variables in the formulation or manufacturing process. To accomplish visual observation, suitable lighting of the vessel contents and clear visibility in the bath are essential. Drugs like Furosemide, Cisplatin and Nifedipine, which are photosensitive require appropriate consideration so that the photo degradation can be minimised. Currently, light sensitive drugs are processed for dissolution testing either by making the whole room dark and/or by use of sodium vapour lamps that consume high energy and are inconvenient. Sometimes the dissolution bath is covered with foil or any other adhoc design, which limits the observation of the dosage form in the vessel. For light sensitive drugs amber colour light is recommended for reducing the photo degradation.

Figure 2: Screenshot of iDisso with simultaneous view of all the six jars

5. Dissolution studies with multiple time points: Extended release formulations are subjected to dissolution testing from minimum of 24 hours to several days depending on the type and purpose of the dosage form. For extended release formulations multiple dissolution time points are analysed for drug concentrations. During the long dissolution hours the particles have high probability of clinging to the sides of the vessel, there could be coning or mounding directly under the apparatus, particles might float at the surface of the medium, film-coated tablets tend to stick to the vessel, and/or off-centre mounds might be formed. While designing a study with number of time points, visual observation is a strong indication of the dissolution process and it would be highly advantageous to keep track of uneven distribution of particles throughout the vessel.

6. Dearation of the dissolution medium: Dissolution medium showing air bubbles can prevent proper wetting of the dosage and hinder the drug dissolution process. It's reported that presence of air bubbles around the paddle, dosage form and side walls of vessel result in reduction of per cent drug released up to 10-20 per cent. When the dissolution medium has not been properly deaerated, the analyst may see air bubbles and particles clinging to vessel walls. To assess the need of deaerating the dissolution media, a drug analyst must make careful visual observation of the vessel, apparatus or dosage unit, sheen on the apparatus is also a sign of air bubbles.

7. Anomalous behaviour of dosage forms: Sometimes anomalous dissolution behaviour may be observed because of floating chunks of tablet, spinning, coning, mounding, gumming, swelling, capping, 'clam shell' erosion, off-centre position, sticking, particles adhering to apparatus or vessel walls or clear particles. Of primary concern is coning, which results in a cone shaped mass of disintegrated, insoluble solids at the bottom of the Apparatus 2 vessel. Pellicles or analogous formations, such as transparent sacs or rubbery, swollen masses surrounding the capsule contents indicate the drug losses that need to be accounted for achieving maximum efficacy.

Figure 3: Screenshot of jar 1 with magnified view of the tablet

8. Aid to current documentation systems: Documenting observations by drawing sketches and taking photographs or videos can be instructive and helpful for those who are not able to observe the real time dissolution test. Observations are especially useful during method development and formulation optimisation. It is important to note that only analytical method results are no longer sufficient for record keeping purposes.

In today's time of automation of dissolution instruments from the stage of dissolution sampling to dilution, mixing and analysis of collected samples; all the steps could be machine monitored based on the pre-programmed software. In such a state it is very critical to have a camera - based visual monitoring to ensure that the processes like dissolution and disintegration are functioning as programmed by the software. Just a glimpse of captured images can give the confidence for the data collected and reduce the human effort of visual inspection at various intervals for future reference. Any discrepancy obtained on analysis of dissolution aliquots can be easily cross verified from the video file recorded during the study. An integrated solution with a user friendly interface to observe and record the drug dissolution and disintegration is highly desirable by research scientists since it can provide live view of in-vitro analysis process whenever necessary. A convenient visual monitoring and recording can help the QC analyst and formulator in better understanding of release kinetics and formulation aspects like selection, concentration and behaviour of excipient explored in the formulation.

Study carried out for visual characterisation during dissolution testing

We have used a dissolution tester (EDT-08Lx, ELECTROLAB) coupled with iDisso-06 (ELECTROLAB) for quantitative, as well as visual evaluation of osmotically controlled bilayered extended release tablets. It was possible to regulate and monitor each and every fraction of dissolution testing throughout the entire study; since the software has a default imaging facility, which captures images at pre-programmed intervals. Uninterrupted video recording of the dissolution test was utilised during experimentation. Documenting observations by taking photographs and videos was quite instructive and helpful in recording and analysing the data. While visual monitoring we could remotely view the dissolution process via browser enabled network PC. It proved to be a helpful tool in evaluation of out of specification (OOS) and out of trend (OOT) data. Some of the screenshots taken during the study are shown in Fig 1, 2 and 3.

It is evident from the Fig 1, 2 and 3 that data could be viewed from various angles and magnified dosage form images could also be captured. Such data will be valuable to assess the changes in surface characteristics during dissolution testing. The imaging was helpful in selecting right excipients while dosages form development and formulation optimisation.


It is imperative to visually observe the behaviour of the dosage form throughout the dissolution testing run. It could provide important insight to drug development processes and dissolution evaluation. Visual monitoring, recording and documentation of dissolution process are most critical parameters specified by USP 34 under the heading of Dissolution Testing validation. Hence, visual imaging techniques have potential applications in assessment of dissolution behaviour of novel drug delivery systems. Moreover, R&D, QC and QA departments could periodically record the dosage forms undergoing dissolution for record keeping purposes as a supplement to the analytical results.

Acknowledgement: Authors would like to express their sincere gratitude to ELECTROLAB for providing the facility to carry out the dissolution study.

Collins, C. C., Vibration-What Is It and How Does It Affect Dissolution Testing, Dissolution Technologies, 1998, 5(4), 16-18.
Gray, V. A., Brown, C. K., Dressman, J. B., Leeson, L. J., A New General Chapter on Dissolution, Pharmacopeial Forum, 2001, 27(6), 3432-3439.
Moore, T.W., Dissolution Testing: a Fast, Efficient Procedure for Degassing Dissolution Medium, Dissolution Technologies, 1998, 3(2), 3-5.
Queshi, S. A. and McGilveray, I. J., Impact of Different Deaeration Methods on the USP Dissolution Apparatus Suitability Test Criteria, Pharm. Forum, 1994, 20(6), 8565-66.
Rohrs, B R, Dissolution Method Development for Poorly Soluble Compounds, Dissolution Technologies, 2001, 8(3), 6-12
Tadey T, Carr G, "Dissolution Testing for Solid Oral Dosage Forms", Pharmaceutical Formulation and Quality, July/August 2009, 11(4), 22-27.
US FDA/CDER, Guidance for Industry, "Dissolution testing of immediate release solid oral dosage forms", 1997.
U.S. FDA/CDER, Guidance for Industry: Immediate release solid oral dosage forms, "Scale-up and post approval changes: chemistry, manufacturing, and controls, in vitro dissolution testing and in-vivo bioequivalence documentation", 1995.
USP, General Chapters <1092>, The Dissolution Procedure: Development And Validation.
Vivian A. Gray "Identifying Sources of Error and Variability in Dissolution Calibration and Sample Testing." American Pharmaceutical Review, (2002) Volume 5, Issue 2, Pages 8-13.
Wang Q, Fotaki N, Mao Y, "Biorelevant Dissolution: Methodology and Application in Drug Development", Dissolution Technologies, August 2009, 6-12.
Zhang H, Yu L, "Dissolution Testing for Solid Oral Drug Products: Theoretical Considerations", American Pharmaceutical Review, September/October 2004, 7(5), 26-31.

(The authors can be contacted at singhkavi@gmail.co Kavita Singh is from CU Shah College of Pharmacy, SNDT Women's University, Mumbai, Aditya Marfatia is from ELECTROLAB, Goregaon (East ), Mumbai and Amrita Bajaj is with SVKM's Dr Bhanuben Nanavati College of Pharmacy, Mumbai)


FEEDBACK: We would love to hear from you -- what you like about our content, what you dont, and even how you think we can improve. Please send your feedback to: editorial.ep@expressindia.com

Copyright 2001: The Indian Express Limited. All rights reserved throughout the world. This entire site is compiled in Mumbai by the Business Publications Division (BPD) of The Indian Express Limited. Site managed by BPD.